
Lyka Labs Ltd is Rated Strong Sell
2026-06-11 10:10:22Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 11 June 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Lyka Labs Ltd Locks at Upper Circuit With 8.19% Gain — Buyers Queue, Sellers Absent
2026-06-10 10:00:10At Rs 77.05, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Lyka Labs Ltd locked at its upper circuit of 8.19% on 10 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Read full news article
Lyka Labs Ltd Locks at Upper Circuit With 9.99% Gain — Buyers Queue, Sellers Absent
2026-06-09 14:00:09At Rs 70.05, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Lyka Labs Ltd locked at its upper circuit of 9.99% on 09 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Read full news article
Lyka Labs Ltd is Rated Strong Sell
2026-05-29 10:10:22Lyka Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Jan 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 29 May 2026, providing investors with the latest perspective on the company’s position.
Read full news articleAre Lyka Labs Ltd latest results good or bad?
2026-05-26 19:24:14Lyka Labs Ltd's latest financial results for Q4 FY26 reveal a concerning operational landscape. The company reported a net loss of ₹7.61 crore, a significant reversal from profitability in the same quarter last year, which indicates a severe decline in financial health. Revenue for the quarter was ₹28.03 crore, reflecting a year-on-year decrease of 16.15%, marking the lowest quarterly revenue in seven quarters. This decline suggests persistent demand weakness and potential market share erosion. The operating margin turned deeply negative at -23.05%, the lowest level recorded, indicating severe cost pressures and operational inefficiencies. Additionally, the profit before tax swung to a loss of ₹8.59 crore, further underscoring the operational challenges faced by the company. Employee costs surged significantly, contributing to a ballooning employee cost-to-sales ratio of 46.06%, raising questions about wor...
Read full news article
Lyka Labs Q4 FY26: Steep Losses Amid Operational Crisis Signal Deepening Distress
2026-05-25 22:30:51Lyka Labs Ltd. plunged into severe operational distress in Q4 FY26, reporting a consolidated net loss of ₹7.61 crores compared to a profit of ₹1.77 crores in Q4 FY25—a staggering deterioration of 529.94%. The micro-cap pharmaceutical company, with a market capitalisation of ₹221.00 crores, saw revenues contract 16.15% year-on-year to ₹28.03 crores whilst operating margins collapsed into deeply negative territory at -23.05%, marking the worst quarterly performance in recent history.
Read full news article
Lyka Labs Ltd Locks at Lower Circuit With 4.69% Loss — Sellers Queue, No Buyers in Sight
2026-05-18 12:00:05At Rs 58.73, Lyka Labs Ltd locked at its lower circuit on 18 May 2026, falling 4.69% within a 5% price band. The session ended with unfilled supply as sellers queued at the floor price but buyers remained absent, freezing trading and highlighting the liquidity challenges faced by this micro-cap pharmaceutical stock.
Read full news article
Lyka Labs Ltd is Rated Strong Sell
2026-05-18 10:10:16Lyka Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Jan 2026, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 18 May 2026, providing investors with the latest insights into its performance and prospects.
Read full news articleLyka Labs Limited - Reply to Clarification- Financial results
03-Dec-2019 | Source : NSELyka Labs Limited Labs Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Lyka Labs Limited - Other General Purpose
28-Nov-2019 | Source : NSELyka Labs Limited has informed the Exchange regarding Disclosure of Related Party Transaction disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Lyka Labs Limited - Updates
22-Nov-2019 | Source : NSELyka Labs Limited has informed the Exchange regarding 'This is to inform pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, that the Company has entered into Loan Agreement with International Asset Reconstruction Company Private Limited (hereinafter referred to as IARC ).
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available






